Syngene International shares experienced a sharp decline of 10.64% to Rs 485.95, making it one of the prominent losers on the Nifty Midcap 150. The stock's movement reflected the broader bearish market sentiment that gripped the indices during the trading session.

Market Performance Context

The broader market indices witnessed significant declines, with the Sensex falling 769.67 points to close at 81,537.70, representing a 0.94% drop. Similarly, the Nifty declined by 241.25 points to 25,048.65, marking a 0.95% decrease. Syngene International was not alone in its decline, as other major losers on the Nifty Midcap 150 included:

Annual Financial Performance

Syngene International's yearly financial results demonstrate a mixed performance trajectory over the past five years:

The company achieved revenue growth from Rs 3,488.60 crore in 2024 to Rs 3,642.40 crore in 2025. However, net profit declined from Rs 510.00 crore to Rs 496.20 crore during the same period. The debt-to-equity ratio remained low at 0.03, indicating strong financial stability.

Quarterly Performance Analysis

The consolidated quarterly financial performance reveals significant volatility in recent quarters:

The most recent quarter ending December 2025 showed revenue of Rs 917.10 crore but a dramatic decline in net profit to Rs 15.00 crore, compared to Rs 183.30 crore in March 2025.

Corporate Developments

Syngene International has announced several corporate actions and regulatory communications. The company declared a final dividend of Rs 1.25 per share, representing 12.5% with an effective date of June 27, 2025. Additionally, the company has scheduled investor presentations and earnings calls as part of its regular disclosure obligations under SEBI regulations.

The stock's current trading price of Rs 485.95 reflects the challenging market conditions and investor sentiment surrounding the company's recent financial performance.

Syngene International has announced a significant revision to its financial outlook for FY26, projecting a decline of 2-3% compared to its previous forecast of mid-single digit growth. This updated guidance represents a notable shift in the company's expectations for the upcoming fiscal year.

Revised Financial Outlook

The pharmaceutical services company has adjusted its growth projections substantially, moving from an anticipated positive growth trajectory to expecting a contraction in business performance. The following table illustrates the change in outlook:

Impact on Business Expectations

This revision in guidance reflects a significant change in the company's assessment of market conditions and business prospects for FY26. The shift from expecting mid-single digit growth to anticipating a 2-3% decline indicates that Syngene International is now taking a more conservative approach to its financial projections.

The updated forecast suggests that the company is adjusting its expectations based on current market dynamics and operational considerations that have emerged since the previous guidance was issued.